Clinical findings published in the April issue of Diabetologia, the official journal of the European Association for the Study of Diabetes NEW YORK, April 05, 2021 (GLOBE NEWSWIRE) -- RenalytixAI plc (LSE: RENX) (NASDAQ: RNLX), announced today that KidneyIntelX™ more accurately predicted
NEW YORK, March 15, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, provides an update
RNS Number : 1874S Renalytix AI PLC 15 March 2021 Renalytix AI plc (" RenalytixAI " or the " Company ") Update on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics NEW YORK , March 15, 2021 - Renalytix AI plc (LSE : RENX) (NASDAQ:
NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that
RNS Number : 2460R Renalytix AI PLC 04 March 2021 Renalytix AI plc ("RenalytixAI", the "Company" or the "Group") Issue of shares under the 2020 Employee Share Purchase Plan, PDMR Dealing and Total Voting Rights New York , 4 March 2021 - Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX),, an
NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“RenalytixAI” or the “Company”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance
RNS Number : 8363Q Renalytix AI PLC 02 March 2021 RenalytixAI Reports Financial Results for Second Quarter of Fiscal Year 2021 NEW YORK , March 2, 2021 - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX) ("RenalytixAI" or the "Company"), an artificial intelligence-enabled in vitro diagnostics
RNS Number : 8349Q Renalytix AI PLC 02 March 2021 Renalytix AI plc ("RenalytixAI", the "Company" or the "Group") Half-year Report Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), ("RenalytixAI" or the "Company"), an artificial intelligence-enabled in vitro diagnostics company, focused on
Innovative partnership to enable health system-wide approach to help delay or prevent progression in the earliest stages while advancing genetics research for detection, prognosis and treatment of chronic kidney disease NEW YORK and SALT LAKE CITY, Feb.
RNS Number : 1616Q Renalytix AI PLC 24 February 2021 This announcement contains inside information Renalytix AI plc (" RenalytixAI " or the " Company ") The University of Utah and RenalytixAI Partner to Drive Innovation in Kidney Health Innovative partnership to enable health system-wide